Siren LLC’s Hemab Therapeutics COAG Stock Holding History
Bought
Maintained
Sold
Other funds holding COAG
Siren LLC's COAG Position: Q3 2026 in Review
Siren LLC increased its Hemab Therapeutics (COAG) stake by 13% in Q3 2026, buying an estimated $12.3M and bringing the position to 2,366,235 shares worth $73M. The position accounts for 1.72% of the portfolio, ranked #16.
Siren LLC first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. The position peaked at $76.6M in Q2 2026. 89 funds tracked by Wall St. Rank hold COAG as of Q3 2026.
- Siren LLC held 2,366,235 shares of Hemab Therapeutics worth $73M as of Q3 2026.
- Siren LLC bought 279,401 Hemab Therapeutics shares in Q3 2026, an estimated $12.3M.
- Hemab Therapeutics made up 1.72% of Siren LLC's portfolio in Q3 2026, its #16 holding.
- Siren LLC first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Siren LLC's Hemab Therapeutics position peaked at $76.6M in Q2 2026.
- 89 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.
Based on Siren LLC's 13F filing for Q3 2026, filed 12 Nov 2026.